Comparison
While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
KPV is 3 amino acids long, whereas Liraglutide is longer as it has a length of 31 amino acids. KPV is made up of a sequence of Lysine, Proline, Valine. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
KPV
POMC
Liraglutide
GCG